--- title: "We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate" type: "News" locale: "en" url: "https://longbridge.com/en/news/281687967.md" description: "Cocrystal Pharma (NASDAQ:COCP) is facing concerns over its cash burn rate, having $7.0 million in cash and a cash burn of $8.2 million over the past year, indicating a cash runway of about 10 months. Although the company reduced its cash burn by 50% recently, its market capitalization of $21 million means that cash burn represents 39% of its value, raising potential dilution risks for shareholders if new shares are issued. Overall, while the reduction in cash burn is promising, the situation remains risky." datetime: "2026-04-04T14:07:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281687967.md) - [en](https://longbridge.com/en/news/281687967.md) - [zh-HK](https://longbridge.com/zh-HK/news/281687967.md) --- # We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? Given this risk, we thought we'd take a look at whether **Cocrystal Pharma** (NASDAQ:COCP) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. ## When Might Cocrystal Pharma Run Out Of Money? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In December 2025, Cocrystal Pharma had US$7.0m in cash, and was debt-free. Importantly, its cash burn was US$8.2m over the trailing twelve months. Therefore, from December 2025 it had roughly 10 months of cash runway. To be frank, this kind of short runway puts us on edge, as it indicates the company must reduce its cash burn significantly, or else raise cash imminently. The image below shows how its cash balance has been changing over the last few years. NasdaqCM:COCP Debt to Equity History April 4th 2026 Check out our latest analysis for Cocrystal Pharma ## How Is Cocrystal Pharma's Cash Burn Changing Over Time? Cocrystal Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. As it happens, the company's cash burn reduced by 50% over the last year, which suggests that management are mindful of the possibility of running out of cash. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. ## How Easily Can Cocrystal Pharma Raise Cash? There's no doubt Cocrystal Pharma's rapidly reducing cash burn brings comfort, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund further growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Since it has a market capitalisation of US$21m, Cocrystal Pharma's US$8.2m in cash burn equates to about 39% of its market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution. ## How Risky Is Cocrystal Pharma's Cash Burn Situation? Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Cocrystal Pharma's cash burn reduction was relatively promising. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. On another note, Cocrystal Pharma has **7 warning signs** (and 4 which can't be ignored) we think you should know about. Of course **Cocrystal Pharma may not be the best stock to buy**. So you may wish to see this **free** collection of companies boasting high return on equity, or this list of stocks with high insider ownership. ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [COCP.US](https://longbridge.com/en/quote/COCP.US.md) ## Related News & Research - [Lynozyfic® shows quick, significant responses in all second-line-plus systemic AL amyloidosis patients.](https://longbridge.com/en/news/287274655.md) - [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md) - [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md) - [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md) - [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md)